Recent Lisata prize Marea touts ‘exciting’ lipid disorder phase 2 win, mulls obesity potential

Fresh from a merger with oncology drugmaker Lisata Therapeutics, cardiometabolic biotech Marea Therapeutics has revealed results from the first part of a phase 2b study showing its drug candidate MAR001 significantly reduced levels of fat in the blood of patients with hypertriglyceridemia.